A. Thareau Vaury

Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer

Stephen Chan, Gilles Romieu, Jens Huober et al. · Journal of Clinical Oncology · 2009 · 119 citations

Medicine, Oncology, Pharmacology +14

Everolimus for treatment-refractory seizures in TSC

David Neal Franz, John A. Lawson, Hiroko Ikeda et al. · Neurology Clinical Practice · 2018 · 107 citations · Full text

Medicine, Neurology, Pharmacotherapy +14

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC).

Robert J. Motzer, Carlos H. Barrios, Tae Min Kim et al. · Journal of Clinical Oncology · 2013 · 70 citations

Medicine, Oncology, Pharmacology +16

Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

Luis G. Paz-Ares, Sedat Altuǧ, A. Thareau Vaury et al. · BMC Cancer · 2010 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC

Gerald Schmid‐Bindert, A. Chemaissani, J.R. Fischer et al. · Journal of Clinical Oncology · 2009 · 12 citations

Medicine, Oncology, Pharmacology +17